Antigen Receptor As Oncogene: Understanding CARD11 Mutations In B Cell Malignancy
Funder
National Health and Medical Research Council
Funding Amount
$607,395.00
Summary
More than 5000 Australians are newly diagnosed as lymphomas. Recent technology identified many candidate genes for lymphomas, however it still remains unclear how each mutated gene distorts signalling molecules inside tumours cells. By introducing one of recurrent mutated genes, CARD11 into mouse B cells, we will examine how this mutation affects normal signalling pathways and B cell functions. We hope this project will provide a guidance to use forthcoming drugs to target specific molecules.
The Oncogenic Function Of A Histone H3K9 Demethylase And Its Contribution To The Aggressive Malignant Phenotype Of Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$762,501.00
Summary
In contrast to the significant improvements in the treatment of acute lymphocytic leukaemia, advances in acute myeloid leukaemia (AML) therapy have been limited. The difficulty in treating AML is thought to arise from a drug-resistant subpopulation of leukaemic stem cells (LSC) that are capable of reinitiating disease after chemotherapy. This project will characterise a key regulator of LSC and provide insights into an important oncogenic process that gives rise to the aggressive and often fatal ....In contrast to the significant improvements in the treatment of acute lymphocytic leukaemia, advances in acute myeloid leukaemia (AML) therapy have been limited. The difficulty in treating AML is thought to arise from a drug-resistant subpopulation of leukaemic stem cells (LSC) that are capable of reinitiating disease after chemotherapy. This project will characterise a key regulator of LSC and provide insights into an important oncogenic process that gives rise to the aggressive and often fatal AML.Read moreRead less
Defining The Myb-p300 Dependent Transcriptional Program In Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$603,632.00
Summary
MYB is a “cancer gene” which turns other genes on or off. MYB is needed by leukaemia cells but also for normal blood cell formation. We have found that interaction between the MYB protein and a protein called p300 is more critical for growth of leukaemia cells than for normal cells. Here we aim to identify a set of MYB/p300 co-regulated genes that are needed by leukaemia cells for the continued growth or survival. Some of these genes may be targets for developing new leukaemia drugs.
Targeting Of The Myb-p300 Interaction In Myeloid Leukaemogenesis
Funder
National Health and Medical Research Council
Funding Amount
$625,980.00
Summary
MYB is a “cancer gene” which turns other genes on or off. MYB is needed by leukaemia cells but also for normal blood cell formation. This project aims to show that blocking interaction between the MYB protein and another protein called p300 is a promising strategy for leukaemia treatment, as leukaemia cells are more dependent on this interaction than normal cells. New molecules to block the MYB-p300 interaction will also be designed and tested; these may form a basis for new leukaemia drugs.